DE69815100D1 - Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten - Google Patents

Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten

Info

Publication number
DE69815100D1
DE69815100D1 DE69815100T DE69815100T DE69815100D1 DE 69815100 D1 DE69815100 D1 DE 69815100D1 DE 69815100 T DE69815100 T DE 69815100T DE 69815100 T DE69815100 T DE 69815100T DE 69815100 D1 DE69815100 D1 DE 69815100D1
Authority
DE
Germany
Prior art keywords
combination
taxane
analogs
derivatives
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69815100T
Other languages
English (en)
Other versions
DE69815100T2 (de
Inventor
Teresa Barlozzari
Andreas Haupt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of DE69815100D1 publication Critical patent/DE69815100D1/de
Application granted granted Critical
Publication of DE69815100T2 publication Critical patent/DE69815100T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE69815100T 1997-03-13 1998-03-09 Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten Expired - Lifetime DE69815100T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/819,101 US6103698A (en) 1997-03-13 1997-03-13 Dolastatin-15 derivatives in combination with taxanes
US819101 1997-03-13
PCT/US1998/004594 WO1998040092A1 (en) 1997-03-13 1998-03-09 Dolastatin-15 derivatives in combination with taxanes

Publications (2)

Publication Number Publication Date
DE69815100D1 true DE69815100D1 (de) 2003-07-03
DE69815100T2 DE69815100T2 (de) 2004-02-05

Family

ID=25227196

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815100T Expired - Lifetime DE69815100T2 (de) 1997-03-13 1998-03-09 Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten

Country Status (30)

Country Link
US (2) US6103698A (de)
EP (1) EP0981358B1 (de)
JP (1) JP2001514659A (de)
KR (1) KR100555604B1 (de)
CN (1) CN1157223C (de)
AT (1) ATE241376T1 (de)
AU (1) AU728027B2 (de)
BG (1) BG64338B1 (de)
BR (1) BR9808249A (de)
CA (1) CA2282720C (de)
CO (1) CO4940498A1 (de)
CZ (1) CZ293905B6 (de)
DE (1) DE69815100T2 (de)
DK (1) DK0981358T3 (de)
ES (1) ES2200317T3 (de)
HK (1) HK1026851A1 (de)
HR (1) HRP980125A2 (de)
HU (1) HU228860B1 (de)
ID (1) ID23900A (de)
IL (2) IL131597A0 (de)
NO (1) NO323894B1 (de)
NZ (1) NZ337416A (de)
PL (1) PL197834B1 (de)
PT (1) PT981358E (de)
RU (1) RU2218174C2 (de)
SK (1) SK285133B6 (de)
TR (1) TR199902244T2 (de)
TW (1) TWI277426B (de)
WO (1) WO1998040092A1 (de)
ZA (1) ZA982093B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20050192443A1 (en) * 2000-11-08 2005-09-01 Lorus Therapeutics Inc. Biological response modifier for the treatment of cancer
US20040101511A1 (en) * 2000-11-08 2004-05-27 Young Aiping H Combination preparation of a biological response modifier and an anticancer agent and uses thereof
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
CN102985439B9 (zh) 2010-02-12 2016-08-03 制药科学股份有限公司 Iap bir结构域结合化合物
CN115698032A (zh) * 2020-06-03 2023-02-03 中外制药株式会社 困难序列的高效的肽缩合法
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5676978A (en) 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
DE69230824T2 (de) 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
US5250683A (en) * 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
US5227400A (en) * 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
FR2688518B1 (fr) * 1992-03-13 1994-05-06 Rhone Poulenc Rorer Sa Procede de preparation de derives du taxane.
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5248796A (en) * 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
CA2151953A1 (en) * 1992-12-16 1994-06-23 Andreas Haupt "dolostatin analog" (novel peptides, the preparation and use thereof)
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
CA2129282A1 (en) 1993-09-29 1995-03-30 George Weber Method for the treatment of neoplastic disease utilizing taxol and tiazofurin
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5494930A (en) * 1994-06-02 1996-02-27 Shimizu; Yuzuru Caribenolide I
US5525613A (en) * 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
DE69534535T2 (de) 1994-12-15 2006-07-06 Baker Norton Pharmaceuticals, Inc., Miami Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung

Also Published As

Publication number Publication date
ZA982093B (en) 1999-09-12
KR100555604B1 (ko) 2006-03-03
EP0981358A1 (de) 2000-03-01
IL131597A0 (en) 2001-01-28
IL131597A (en) 2006-06-11
TWI277426B (en) 2007-04-01
AU728027B2 (en) 2001-01-04
CO4940498A1 (es) 2000-07-24
WO1998040092A1 (en) 1998-09-17
ATE241376T1 (de) 2003-06-15
PL197834B1 (pl) 2008-04-30
CN1252728A (zh) 2000-05-10
ID23900A (id) 2000-05-25
US6103698A (en) 2000-08-15
PT981358E (pt) 2003-09-30
JP2001514659A (ja) 2001-09-11
NZ337416A (en) 2001-05-25
DK0981358T3 (da) 2003-09-22
HUP0001381A3 (en) 2001-12-28
CZ321199A3 (cs) 2000-02-16
HUP0001381A2 (hu) 2000-10-28
RU2218174C2 (ru) 2003-12-10
AU6694598A (en) 1998-09-29
ES2200317T3 (es) 2004-03-01
PL335579A1 (en) 2000-05-08
BR9808249A (pt) 2000-05-16
NO323894B1 (no) 2007-07-16
US6632795B1 (en) 2003-10-14
NO994408D0 (no) 1999-09-10
CA2282720C (en) 2009-12-29
BG103728A (en) 2000-04-28
SK285133B6 (sk) 2006-07-07
HK1026851A1 (en) 2000-12-29
DE69815100T2 (de) 2004-02-05
CN1157223C (zh) 2004-07-14
CA2282720A1 (en) 1998-09-17
HU228860B1 (en) 2013-06-28
TR199902244T2 (xx) 1999-12-21
EP0981358B1 (de) 2003-05-28
HRP980125A2 (en) 1999-02-28
BG64338B1 (bg) 2004-10-29
SK125199A3 (en) 2000-08-14
NO994408L (no) 1999-11-10
CZ293905B6 (cs) 2004-08-18
KR20000076211A (ko) 2000-12-26

Similar Documents

Publication Publication Date Title
EP1181013A4 (de) Verfahren und zusammansetzung zur behandlung von krebs
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
CY1105399T1 (el) Μεθοδος επιλεκτικης υποκαταστασεως των ταξανων
DE69703294T2 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
NZ245795A (en) The use of paclitaxel formulations with reduced haematologic toxicity to treat tumours
HU9602942D0 (en) Taxane class derivative based pharmaceutical compositions
FI955424A (fi) Syklodekstriinien kanssa muodostettuja taksoli- ja taksoteeri- tai Taxus-uuteinkluusiokomplekseja ja niiden valmistus ja käyttö
DE69815100D1 (de) Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
DE69430797T2 (de) C9 taxanderivate und diese enthaltende pharmazeutische zusammensetzungen
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
DE60111614D1 (de) Taxan-derivate für die behandlung von krebs
EP0793499A4 (de) Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof
SI1287854T1 (sl) Kombinacija DMXAA in paklitaksela ali docetakselaproti raku
CA2206567A1 (en) Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ABBOTT GMBH & CO. KG, 65205 WIESBADEN, DE

8364 No opposition during term of opposition